U.K. preparing for value-based drug-pricing system

03/24/2013 | Reuters

Beginning in 2014, Britain's National Institute for Health and Clinical Excellence will approve and price drugs based on broader measures, including the benefits to society. Firms with innovative, badly needed or highly effective medications, for example, could command higher prices. The new value-based initiative will replace the current system that caps the maximum return on investments that drug companies can earn.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY